+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06892522

Evaluating Safety and Effectiveness of Etentamig and ABBV-2001 with Other Drugs in Adults with Multiple Myeloma

Led by AbbVie · Updated on 2026-10-19

602

Participants Needed

36

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Multiple myeloma is a type of blood cancer that affects plasma cells typically found in the bones and bone marrow. This cancer can cause bone pain, fractures, infections, weak bones, and kidney failure. The study is designed to evaluate the safety, effectiveness, and how the body processes two investigational drugs, Etentamig and ABBV-2001, in adults with multiple myeloma, including those newly diagnosed or with relapsed or refractory disease. The study includes eight substudies with dose escalation and expansion phases. Participants in substudies 1-4 will receive increasing doses of Etentamig alone or combined with other drugs like daratumumab, lenalidomide, carfilzomib, and dexamethasone, delivered intravenously or by subcutaneous injection. Substudies 5-8 involve up to two doses of ABBV-2001 combined with oral agents such as iberdomide, mezigdomide, pomalidomide, or lenalidomide. Treatments are given according to dose levels determined during escalation phases, and the total study duration is about 130 months. Throughout the study, participants will attend regular hospital or clinic visits for medical assessments, blood tests, and side effect monitoring. Researchers will use questionnaires and other evaluations to track treatment effects and adverse events. The primary outcomes include monitoring adverse events and dose-limiting toxicities, with secondary measures including response rates, progression-free survival, duration of response, time to progression, and minimal residual disease negativity over the course of the study.

CONDITIONS

Brief Title

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here